Skip to content

JBIO JBIO Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$4.73M+11.5%
Vera Therapeutics logo
Vera TherapeuticsVERA
$3.94M+157%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$14.02M+4,735%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$2.18M
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$0-100%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$0-100%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's stock issuance proceeds?
JBIO (JBIO) reported stock issuance proceeds of $45K in Q1 2026.
How has JBIO's stock issuance proceeds changed year-over-year?
JBIO's stock issuance proceeds increased by 104.5% year-over-year, from $22K to $45K.
What is the long-term trend for JBIO's stock issuance proceeds?
Over 2 years (2021 to 2025), JBIO's stock issuance proceeds has grown at a -97.4% compound annual growth rate (CAGR), from $126.95M to $88K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.